The Future of Clay Siegall Seattle Genetics

Posted on

Cancer is a disease that has plagued most economies even for those of developed countries like the USA. One company that stands tall and is determined to change the cancer narrative completely is Seattle Genetics. Headquarters in Cascade business park, the clustered buildings that hosts Seattle Genetics does not communicate anything that would suggest the involvement of this giant company to the deadly disease; however as you get inside the building you will meet a triangular sculpture green in color symbolizing the human antibody.

Since its establishment in 1998 Seattle Genetics has been involved with research works, manipulation and manufacturing of drugs that help with cancer therapy. The working principle behind Seattle Genetics has always been connecting the drugs with the antibodies that reside within the body. Through the drugs the company has been able to treat cancer by destroying the cancerous cells from inside.

Despite the fact that this strategy may look simple, in reality it has been able to hurl Seattle Genetics to the top charts in the market. Currently Seattle Genetics boasts of a market value of over $ 10 billion and an employee population of 900. Thanks to this, the company now ranks among the few companies with the possibilities of changing from biotech to pharma. In order to achieve this the company is required to invest heavily in research and development and also increase its employee base with 200 employees. The Seattle Genetics community is one that is rallying behind the promotion of this company to a pharmaceutical company as it will help them have a partner they can count on to mitigate the cancer plague in their community.

About Clay Siegall

Clay Siegall is a renowned biotech who has helped found Seattle Genetics the biotechnology firm that specializes in research and development of therapeutic cancer drugs. Dr. Clay Siegall is quite reputable, in addition to contributing to the health sector through his company, Clay has also helped develop and manufacture a number of drugs that have been approved by FDA.

Dr. Clay is a graduate of George Washington University where he studied his bachelor’s degree in genetics before advancing it with a Phd. In addition to being a healthcare provider Clay Siegall is also a distinguished leader. His leadership role in Seattle Genetics is quite commendable as he has helped the company make a lot of progress. To prove his prowess, Dr. Clay has been awarded are recommended on multiple account including the 2012’s Pacific Northwest Ernst & Young Entrepreneur of the Year.

Mikhail Blagosklonny’s Journeys with Anti-aging Drug Paying Returns

Posted on

Mikhail Blagosklonny, a renowned scientist in cancer and aging, and his contributions in anti-aging drugs are paying greater returns in the recent years. The hyperfunction theory put forward by Blagosklonny in the 2000s became the basis of all the anti-aging research in the later years. Though it was ridiculed by other researchers in the initial years, now it is proving to be a significant milestone in the development of treating age related health problems. With hyperfunction theory, Blagosklonny explained that aging should be considered as the continuation of growth that is driven by some types of signaling pathways like TOR or Target of Rapamycin. Until then, it was believed that aging was a functional decline caused by random molecular damages – something that cannot be prevented.The TOR model predicted that rapamycin and other rapalogs could be used to prevent diseases and treat aging. It says that by using proper dosages and schedules, people can extend their healthy lifespan. Though it was ridiculed by many peer reviewers, it also predicted that five years from then, people would take it as granted. The current development shows that the prediction was accurate and fulfilled. Currently, Evirolimus – a rapamycin analog – ensures immunity in aging people and led to further research in anti-aging drugs. It should be noted that Novartis started working on “Youth Drug” that can delay the various effects of aging and provide better health for older adults. Altogether, the drug targets everything related to aging and ensures a comfortable and healthy condition in the later part of the life.

In 2006, rapamycin was approved as a drug to use for cancer, autoimmunity, metabolic disorders, cardiovascular diseases, age related diseases from osteoporosis to Alzheimer’s, and more. Interestingly, it is safe for daily use for several years and can rejuvenate immunity. By 2010, most of the predictions of the TOR-centric model was found to true. It should be noted that the theory put forward by Blagosklonny also predicts calorie-restriction-mimicking technic of rapalogs and its side effects. It is found that rapamycin can create starvation-like symptoms in some conditions. The induced state caused by rapamycin stops the complications of type II diabetes. The mTOR-centric model suggests the reversible insulin resistance by rapamycin can increase the longevity of humans as it can lead to decreased mTOR pathway signaling.

Mikhail Blagosklonny works with Roswell Park Cancer Institute as a professor of Oncology. He is associated with a number of journals and works as the editor-in-chief of Cell Cycle and Oncotarget. Blagosklonny is also the associate editor of the American Journal of Pathology, PLOS ONE, International Journal of Cancer, and Cancer Biology and Therapy. Apart from aging and cancer, he also researches from clinical investigations to cellular and molecular biology. Blagosklonny wrote more than 300 reviews, research articles, book chapters, and more. Mikhail earned his MD in Internal Medicine from the First Pavlov State Medical University, St. Petersburg. He continued there and earned a Ph.D. in Cardiology and Experimental Medicine. Blagosklonny started his career with New York Medical College as an associate professor of medicine. Later, he joined Ordway Research Institute as a senior scientist, before joining Roswell Park.You can also follow them on Twitter :

Get To Know Oncologist Mikhail Blagosklonny

Posted on

Oncology is simply defined as the study and treatment of tumors. Dr. Mikhail Blagosklonny is scientist expanding oncology with his focus on groundbreaking concepts. He is currently on staff at Roswell Park Cancer Institue as a professor of Oncology. Mr. Blagosklonny studies every aspect of aging and cancer.He earned his MD in Internal Medicine and his Ph. D. in experimental Medicine and Cardiology while attending the First Pavlov State Medical University of St. Petersburg. In 2002 he was the associate professor of medicine at New York Medical College in Valhalla, New York.He was the senior scientist at Ordway Research Institue. In 2009 he became a member of the staff at Roswell Park Cancer Institute as the Professor of Oncology.

His Research Topics Of Interests Include:

*Biogerontology (underlying mechanisms of aging)

*Anti-Aging Drugs


*Targeted Cancer Therapies

Get To Know Oncologist Mikhail Blagosklonny , not only is Mr. Blagosklonny the associate editor of cancer biology and therapy, he also works for both Oncotarget and Cell Cycle as the editor-in-chief. He is also a member of the editorial board of Cell Death and Differentiation. Mr. Blagosklonny is credited with the hypothesis regarding Target OfRapamycin (TOR) Signaling cancer and aging.He offered that Rapamycin could be utilized as a means for life management and treatment. Rapamycin is very well known for its use in the fight against cancer.Known for his zeal as an advocate for Rapamycin, Mr. Blagosklonny’s research varies from a wide array of topics such as:

*Cellular Biology

*Molecular Biology

*Clinical Investigations

The Main Focus Of Mikhail Blagosklonny’s research includes among other things:

*Signal Transduction


*Tumor Suppressors

*Drug Resistance For Normal Cells Selective Protection


*Cell Cycle

*Anti-Cancer Therapeutics


The Author Mikhail Blagosklonny Has Accomplished:

*Over 300 published research articles, book content, and reviews.

*Author of aging hyperfunction theory

*Author of articles about cell Cyclotherapy and chemotherapeutic engineering

*Associate editor for PLOS ONE, the American Journal of Pathology, and International Journal of Cancer.

He has a blog@: where you can get to know Mikhail and hyperlink to a new window at google scholar where you can check out his articles.

The Top 5 List Of Articles From Mikhail Blagosklonny:

  1. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009
  2. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012
  3. Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha
  4. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death
  5. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms

Mikhail is known for loving his job as an oncologist and for sincerely believing in the human ability to not only control cancer but to eradicate it with the use of Rapamycin. He feels that controlling aging is possible as well. When asked what motivated him into his field of work he responded that it was his love for humanity and his vision of seeing a disease-free community that did it.

Omar Boraie Makes Large Donation to Cancer Research

Posted on

It was reported by Newswise in this article – – that Omar Boraie made a large donation to the Rutgers Cancer Institute of New Jersey. With the donation, the Omar Boraie Chair in Genomic Science was created at the institute. An endowed chair is considered a firm commitment by a university to dedicate themselves to a first-class academic discipline as well as guarantee their continued support of the program in the future. The donation that Omar Boraie pledged was $1.5 million that will be matched to be $3 million in total for the chair. In a statement of Director of Rutgers Cancer Institute, Dr. Robert DiPaola, said that Omar Boraie had been a long term supporter of the institute and that they were thankful for his generosity.

The specialization that Boraie supported was genomic science and precision medicine. This field as explained by, is changing how researchers approach cancer diagnoses and the treatments they prescribe. This is a new field that investigates and treats cancerous tumors on the genetic level. The field came to national prominence when former President Obama announced the start of a Precision Medicine Initiative on a national scale in the effort to find a cure for cancer as well as other diseases. Rutgers Cancer Institue was one of the first research facilities in the United States to use the precision medicine approach on genomic sequencing in patient care.

According to NJ Biz, the person named to the chair was Shridar Ganesan, MD, PhD. He is an Associate Director for Translational Science. He has also been in charge of the precision medicine trials at the institute as well as an Associate Professor of Medicine and Pharmacology at Rutgers Robert Wood Johnson Medical School. He has been internationally recognized top academic researcher by his peers. In a statement about his appointment, he commented that cancer is not a single disease but rather a collection of them. He said that the donation by Boraie will help advance clinical research give new hope to patients and their families.